Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 9/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | FYN | P06241 | 1/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.55 |
| ▸ | GRB2 | P62993 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 2/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 4/20 | 0.49 |
| ▸ | ACHE | P22303 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16197761 | 0.87 | AKR1B1 (0.68) | HSD17B3LCKFYNAKR1B1GRB2 | |
| SCHEMBL724773 | 0.85 | LCK (0.63) | HSD17B3LCKFYNAKR1B1GRB2 | |
| SCHEMBL723311 | 0.85 | LCK (0.63) | HSD17B3LCKFYNAKR1B1GRB2 | |
| SCHEMBL28050487 | 0.84 | ALDH1A1 (0.62) | HSD17B3LCKFYNAKR1B1GRB2 | |
| SCHEMBL20780147 | 0.83 | ALDH1A1 (0.48) | HSD17B3LCKFYNAKR1B1GRB2 | |
| SCHEMBL16197641 | 0.82 | HSD17B3 (0.64) | HSD17B3LCKFYNAKR1B1GRB2 | |
| SCHEMBL2760317 | 0.77 | LCK (0.61) | HSD17B3LCKFYNAKR1B1GRB2 | |
| SCHEMBL532562 | 0.76 | BCHE (0.60) | HSD17B3LCKFYNAKR1B1GRB2 | |
| SCHEMBL10035655 | 0.76 | LCK (0.60) | HSD17B3LCKFYNAKR1B1GRB2 | |
| SCHEMBL13851556 | 0.76 | HSD17B3 (0.54) | HSD17B3LCKFYNAKR1B1GRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221441-B1 | Compounds and methods for assaying activity of lysosomal storage diseases | Cabridge Isotope Laboratories, Inc. (US) | 2019-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221441-B1 | Compounds and methods for assaying activity of lysosomal storage diseases | GBA1, MAN2B1, GBA2 | HSD17B3 250/4885LCK 4767/4885FYN 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.